Merck & Co., Inc.

Merck Wins Summary Judgment in Second Federal Bellwether Case Involving FOSAMAX (alendronate sodium) [Press Release]
Business Wire | 11 hours 31 minutes ago
Merck said today that U.S. District Court Judge John F. Keenan granted summary judgment in Merck's favor in Flemings v. Merck. Flemings is the second of three cases involving FOSAMAX (alendronate sodium) designated by the federal MDL court as a bellwether trial case.

Merck Expresses Confidence in the Efficacy and Safety Profiles of ZETIA (ezetimibe) and VYTORIN (ezetimibe/simvastatin) as Effective Medicines for Managing Elevated Cholesterol [Press Release]
Business Wire | 8 days 12 hours 20 minutes ago
At the American Heart Association meeting today, Merck & Co., Inc. said it is confident in the safety and efficacy profiles of ZETIA® (ezetimibe) and VYTORIN® (ezetimibe/simvastatin), and issued the following comment in response to misinterpretation of results from a small 200-patient imaging study called ARBITER 6.

Merck Receives CHMP Positive Opinion for New Fertility Treatment, ELONVA(R) [Press Release]
PRNewswire | 3 days 16 hours 25 minutes ago
Merck Receives CHMP Positive Opinion for New...Nov. 20 /PRNewswire-FirstCall/ -- Merck & Co., Inc. today announced the Committee for Medicinal...Romanelli,+1-908-423-5088, all of Merck & Co., Inc.

Addex ADX48621 Positive Primate Parkinson's Data [Press Release]
MarketWire | 1 minute ago
GENEVA, SWITZERLAND -- (Marketwire) -- 11/24/09 --

Higher Dose of Merck s COZAAR (losartan potassium tablets) Significantly Reduced Deaths and Hospitalizations Due to Heart Failure In Investigational Study [Press Release]
Business Wire | 6 days 22 hours 32 minutes ago
In an investigational study, Merck's medicine COZAAR (losartan potassium tablets) 150 mg, administered once daily, significantly reduced the risk of all-cause death or hospitalization due to heart failure compared to a lower 50 mg once daily dose of COZAAR. The Merck-sponsored study compared the safety and efficacy of two doses of COZAAR® in patients with chronic heart failure and reduced cardiac function (left ventricular ejection fraction) who were intolerant of angiotensin-converting enzym...

FDA Approves GARDASIL for Use in Boys and Young Men [Press Release]
Business Wire | 38 days 18 hours 12 minutes ago
Merck & Co., Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] for use in boys and men 9 through 26 years of age for the prevention of genital warts caused by human papillomavirus (HPV) types 6 and 11. FDA approval is the first step in an important two-step process. The next step in the process is an Advisory Committee on Immunization Practices vote on whether to recom...

Ligand Earns $2 Million in Milestone Payments from Merck & Co., Inc. [Press Release]
Business Wire | 4 days 22 hours 2 minutes ago
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that it has received $2 million in milestone payments from N. V. Organon, a subsidiary of Merck & Co., Inc., stemming from its research collaboration that is due to expire at the end of December.

New Merck Begins Operations [Press Release]
Business Wire | 19 days 22 hours 32 minutes ago
Merck & Co., Inc. (NYSE: MRK) today outlined its global plans following the completion of Merck's merger with Schering-Plough Corporation announced yesterday. The new Merck is a global health care leader aimed at providing innovative, distinctive products and services that save and improve lives, while satisfying customer needs and creating long term shareholder value.

ARIAD to Present Data on Pan-BCR-ABL Inhibitor AP24534 at 51st American Society of Hematology Meeting [Press Release]
Business Wire | 22 hours 57 minutes ago
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that the Company and collaborating investigators from five major oncology research centers in the United States will present data from a Phase 1 clinical trial of ARIAD’s investigational, multi-targeted kinase inhibitor and pan-BCR-ABL inhibitor, AP24534, at the 51st Annual Meeting of the American Society of Hematology (ASH) being held in New Orleans, Louisiana, December 5-8, 2009. The Phase 1 clinical proof-of-concept data on AP24534...

Merck and Schering-Plough to Complete Merger Today [Press Release]
Business Wire | 20 days 18 hours 49 minutes ago
Merck & Co., Inc. (NYSE: MRK) and Schering-Plough Corporation (NYSE: SGP) today announced that they will complete their merger shortly after 4:00PM ET today. The companies will begin combined operations tomorrow, November 4, 2009. As previously announced, Schering-Plough will change its name to Merck and its common stock will trade under the ticker symbol “MRK” on the New York Stock Exchange.

Critical Alerts For Merck, Monsanto, Urban Outfitters, Petrohawk Energy, and Vistaprint Released By Seven Summits Research [Press Release]
PRNewswire | 4 days 15 hours 1 minute ago
Critical Alerts For Merck, Monsanto, Urban Outfitters, Petrohawk Energy, and Vistaprint... Today's PriceWatch Alerts cover the following stocks: Merck & Co. Inc. , Monsanto Co. , Urban Outfitters Inc. , Petrohawk Energy Corporation...

Fitch Downgrades Merck and Upgrades Schering-Plough to 'A+' Following Merger; Outlook Stable [Press Release]
Business Wire | 19 days 14 hours 43 minutes ago
As a result of the completed merger between Merck & Co., Inc. (Merck) and Schering-Plough Corp. (Schering-Plough) yesterday, Fitch Ratings has downgraded Merck's Issuer Default Rating (IDR) to 'A+' from 'AA-' and upgraded Schering-Plough's IDR to 'A+' from 'BBB+'. Simultaneously, Fitch downgraded Merck's senior unsecured debt and bank loan ratings to 'A+' from 'AA-' and downgraded the short-term IDR and commercial paper rating to 'F1' from 'F1+'. The ratings were also removed from Rating Watc...